Romasulid (Nimesulide) is commonly used to help with symptomatic relief across several clinical domains marked by symptoms related to physical discomfort, inflammation, and fever. It may assist with moderating distressing symptoms and supports comfort in situations requiring short-term therapeutic assistance. Its use is applicable within clinical settings that involve acute or disruptive symptom patterns.

The medicine is considered relevant in contexts involving acute pain and inflammation, such as those arising from soft tissue injuries (like sprains and strains), painful osteoarthritis flares, and specific post-operative discomfort. It is commonly used for the management of primary dysmenorrhea (menstrual cramping) and conditions where acute pain is coupled with fever, such as in certain upper respiratory tract inflammations. Romasulid supports addressing symptom clusters that interfere with daily functioning, providing supportive relief that may assist with maintaining functional stability during these acute phases.

Quick Fact: Supports Management of Pain, Inflammation, and Fever

The core therapeutic benefit is relevant for easing the intensity of three related symptom axes: pain, localized swelling, and elevated body temperature (fever).

Regulatory References

1. European Medicines Agency

The eligibility profile for Romasulid (Nimesulide) is strictly defined by regulatory authorities and centers on age, organ function, and pre-existing health conditions. The medicine is approved for use only in adults and adolescents aged 12 to 18 years.

Absolute Contraindications (Must Not Use)

Romasulid is formally contraindicated in several patient populations. It must not be used by children under 12 years of age. Absolute prohibitions also apply to patients with any degree of hepatic impairment, severe renal impairment (creatinine clearance less than 30 ml/min), or severe heart failure. Use is also prohibited in patients with active gastrointestinal ulceration or bleeding, or a history of recurrent ulceration. Additionally, the medicine is contraindicated during the third trimester of pregnancy and for breastfeeding mothers.

Regulatory Restrictions on Use

For eligible populations, the use of Romasulid is restricted: it must only be used as a second-line treatment and for a maximum treatment duration of 15 days. Patients with mild to moderate renal impairment, or elderly patients, are required to use the medicine with caution, often necessitating clinical monitoring.

Interactions with other medicines and products

Restrictions and Avoidance

Romasulid (Nimesulide) has officially documented interaction patterns that require specific precautions when co-administered with certain medicines or substances. Formal regulatory restrictions state that alcohol abuse and concomitant use of known hepatotoxic drugs must be avoided due to a documented increase in the risk of severe hepatic reactions. The simultaneous use of Romasulid with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including acetylsalicylic acid, is not recommended due to an additive risk of adverse effects.

---

Pharmacodynamic and Exposure Risk

Co-administration with anticoagulants (such as Warfarin) or antiplatelet agents necessitates close monitoring of coagulation status due to an increased risk of bleeding. The medicine may also reduce the effects of diuretics (like Furosemide) and antihypertensives (ACE-Inhibitors/ARBs). In patients with compromised renal function, this combination carries a heightened risk of acute renal failure and requires caution.

As an inhibitor of the CYP2C9 enzyme, Romasulid may increase the plasma concentration of medicines metabolized by this pathway. This interaction is clinically significant for drugs like Lithium, necessitating the monitoring of serum lithium levels, and for Methotrexate and Cyclosporine, where an increase in toxicity is documented. Caution is formally required if Methotrexate is used less than 24 hours before or after Romasulid treatment.

HOW ROMASULID WORKS (MECHANISM OF ACTION)

Romasulid is a small molecule that acts as a relatively selective inhibitor of the enzyme Cyclooxygenase-2 (COX-2). Its core mechanism involves high binding affinity to the active site of COX-2, leading to the competitive blockade of enzyme activity.

This molecular interaction prevents the conversion of arachidonic acid into various prostaglandins (PGs). The resulting reduction in PG synthesis is the primary intracellular consequence of Romasulid, modulating the signaling cascade that PGs mediate.

Beyond COX-2 inhibition, the drug exhibits pleiotropic actions. It downregulates prostaglandin E2 ( PGE2) signaling, which influences the expression of matrix metalloproteinases (MMPs) involved in tissue degradation. Furthermore, Romasulid modulates the activity of phosphodiesterases and influences the production of reactive oxygen species (ROS), contributing to a multi-target physiological modulation of cellular processes.

Official Administration and Dosing Principles

Romasulid, whose active ingredient is Nimesulide, is administered through two primary routes: oral for systemic action and topical for localized use. The foundational principle of its use is to utilize the minimum effective dose for the shortest duration necessary.

---

Standard Systemic Use

For oral systemic administration, the standard adult dose is 100 mg taken twice daily (bid), establishing a maximum recommended daily dose of 200 mg. Oral forms, such as tablets or granules for suspension, must be taken after meals (post-prandial) for proper administration. Granules should be dissolved in a small amount of water immediately before intake. Crucially, the total duration of systemic treatment is strictly limited and must not exceed 15 consecutive days for any indication.

---

Topical Administration

The topical formulation, typically a 2% or 3% gel, is applied locally to the skin. This product should be applied in a thin layer and massaged gently until completely absorbed. Topical application is generally repeated 2 to 3 times daily. Official instructions specify that the gel must not be used with occlusive dressings (bandages) and must never be taken by mouth.

---

Population-Specific Guidelines

Official labeling generally indicates no dosage adjustment is necessary for older adults or for adolescents between 12 and 18 years of age. Use in children under 12 years is contraindicated for both systemic and topical formulations.

Research evidence / Overview of Studies for Romasulid

Evidence for Short-Term Use in Acute Pain

Research was studied for in numerous short-term Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies were applied in research contexts involving fluctuating or unstable symptoms of acute pain, such as after dental procedures or due to acute soft tissue injuries. Researchers monitored patient-reported outcomes describing perceived discomfort by measuring pain intensity scores and the time until the initial changes were measured.

Studies were conducted during periods of increased symptom activity in adult populations to evaluate whether the medicine was associated with changes in physical discomfort. The research so far describes patterns observed in the studies where changes in pain intensity scores were monitored in the observed populations over short intervals. Comparative evidence was also explored against other anti-inflammatory drugs, where findings indicate that studies monitored outcomes related to physical discomfort over the defined short time intervals.

Research Evidence for Primary Dysmenorrhea

Romasulid was studied for the management of primary dysmenorrhea, a condition characterized by fluctuating or episodic manifestations of painful menstrual cramping. The evidence base here is composed of focused RCTs, including double-blind designs, where the research explored outcomes related to physical discomfort during the menstrual phase.

Studies were applied in studies examining patient-reported experiences by using specific questionnaires to measure outcomes related to episodic or acute changes in pain intensity. Some trials also explored objective outcomes like changes in uterine pressure or prostaglandin levels, which are linked to inflammatory states. The findings from these trials describe group patterns where changes were measured during the study period, which contributes to the broader evidence landscape for this condition.

Evidence Base for Painful Osteoarthritis Flares

The evidence structure for painful osteoarthritis flares—a condition involving periods of heightened symptoms and marked by functional limitations—includes a history of RCTs and other trials, some with intermediate follow-up periods of up to six months. Research explored outcomes reflecting daily functioning or activity level, such as specific functional capacity scales, alongside measurements of pain at rest and during movement.

Studies were used in observational settings evaluating daily-life functioning of adults with confirmed OA, mainly in the knee and hip. The findings describe patterns observed in the studies where changes in outcomes related to functional imbalance were measured in the observed populations. Research highlights changes measured during the study period for symptom intensity and variability, with outcomes often being measured against those observed with other compounds evaluated in the same research context.

Research Gaps and Areas of Uncertainty

The current research provides insight into short-term changes, but several limitations prevent a complete understanding of Romasulid's overall profile. The principal evidence gap is the lack of randomized trial data regarding long-term outcomes and repeated use. Furthermore, data for comparisons with some commonly used treatments in specific acute settings remain insufficient. The evidence quality varies across studies based on design, and while some findings describe group patterns, the subgroup findings are uncertain.

Key Studies & References Nimesulide: An Update on its Pharmacological Properties and Therapeutic Use (Systematic Review)

Common questions about Romasulid (FAQ)

---

Q: What is Romasulid prescribed for most often?

A: According to official product information, Romasulid is indicated for the treatment of acute pain and the symptomatic relief of painful osteoarthritis flares. It is also indicated for the symptomatic treatment of primary dysmenorrhea (painful menstrual periods).

Q: Why do official documents state that Romasulid should only be used for certain conditions?

A: Official guidance restricts the medicine to a second-line treatment status. This restriction is primarily in place to minimize the risk of serious side effects, particularly those affecting the liver and the gastrointestinal tract.

Q: What are the general safety classifications for Romasulid?

A: Due to the documented risk of severe hepatic reactions, the medicine is designated for second-line use only. Official safety precautions strictly limit the dose and the maximum treatment duration to 15 days.

Q: Why is Romasulid a prescription-only medicine?

A: The medicine is classified as a second-line treatment and requires close clinical monitoring. This is due to the potential for serious hepatic and gastrointestinal side effects, which necessitate prescription status for controlled use.

Q: Are there specific symptoms that warrant immediate medical attention while on Romasulid?

A: Official product information states that if symptoms compatible with liver injury occur, it is necessary to discontinue the medication and consult a healthcare professional. These symptoms include loss of appetite, nausea, vomiting, abdominal pain, fatigue, or dark urine.

Q: What are the most common side effects of Romasulid according to official sources?

A: Based on official sources, the most commonly reported undesirable effects are gastrointestinal issues. These effects include diarrhea, nausea, and vomiting.

Q: Can Romasulid affect blood pressure?

A: Official documents note that fluid retention and edema (swelling) have been reported in association with this medicine. Official documentation notes that caution is necessary in patient populations with a history of hypertension (high blood pressure).

Q: Can Romasulid cause problems with sleep?

A: Yes, according to official undesirable effects documents, somnolence (drowsiness) is listed as an undesirable effect that has been reported.

Q: Is it normal to feel a change in appetite while taking Romasulid?

A: Loss of appetite, medically known as anorexia, is listed in official warnings. This symptom is listed as compatible with potential liver injury, a situation that necessitates prompt consultation with a healthcare professional.

Q: Does Romasulid have a risk of dependence or addiction?

A: Regulatory contraindications prohibit the use of the medicine in individuals with a history of drug addiction. This information is listed in the official safety documents.

Q: How quickly does Romasulid usually start working?

A: Official documents describe the time it takes for the medicine to reach its highest level in the bloodstream. This peak concentration is typically reached approximately 2 to 3 hours after the oral formulation is taken.

Q: How long does the effect of one dose of Romasulid typically last?

A: The duration of effect is generally related to the half-life of the active metabolite (hydroxynimesulide). This half-life is between approximately 3.2 and 6 hours.

Q: Is the 'half-life' of Romasulid important for how often it is taken?

A: Yes, the half-life is a key factor in determining the correct administration frequency. The terminal half-life of the active substance, Nimesulide, ranges between 2 to 5 hours, and this information informs the frequency of administration recommended in the official labeling.

Q: How does the body generally eliminate Romasulid after it is taken?

A: The body extensively processes the medicine, primarily through metabolism in the liver. The substance is then eliminated mainly through the urine (about 50% of the dose) and also through the faeces (about 29% of the dose).

Q: Is Romasulid used to treat headaches?

A: The medicine is formally indicated for the treatment of acute pain. When prescribed by a healthcare professional, the indication for acute pain may cover various types of discomfort, including headaches.

Q: Does Romasulid interact with common cold or flu medications?

A: Romasulid is not recommended for use with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Many common cold or flu remedies contain NSAIDs, and as such, co-administration with other NSAIDs is not recommended in regulatory documentation.

Q: Are there known interactions between Romasulid and birth control pills?

A: Co-administration with oral contraceptives may be associated with an increased risk of liver damage. This is due to the known potential for liver-related side effects from Romasulid.

Q: Can Romasulid interfere with laboratory blood tests?

A: Yes, official warnings state that treatment must be discontinued if a patient develops abnormal liver function tests. These tests are laboratory blood tests that measure liver enzymes and function.

Q: Does Romasulid have any known impact on fertility?

A: According to the official product information, use of the medicine may impair female fertility. For women actively attempting to conceive, use of the medicine is not recommended in official documents due to this potential effect.

Q: Does Romasulid cause sensitivity to the sun?

A: For the topical gel formulation, there is a specific warning against exposure to direct or solarium sunlight. This measure is advised to reduce the risk of photosensitivity (increased sensitivity to light).

Q: Is it safe to drive or operate machinery after taking Romasulid?

A: Official prescribing information includes a warning that if effects such as dizziness or somnolence (drowsiness) are experienced, one should refrain from driving or operating machines.

Q: Does Romasulid contain gluten, lactose, or common allergens?

A: Official excipient lists indicate that certain oral forms of the medicine may contain lactose. This requires caution for patients with rare hereditary problems such as galactose intolerance.

Storage Requirements

The storage conditions for Romasulid (Nimesulide) are defined by international regulatory standards to maintain product stability. The medicine must be stored below the labeled temperature, typically 25 C or 30 C, and must be protected from light and moisture.

• Container Rules: The product must remain in its original container and be kept tightly closed to prevent environmental exposure. Freezing the product is prohibited.
• Child Safety: All medicine, including Romasulid, must be kept strictly out of the sight and reach of children to prevent accidental ingestion, as mandated by health authorities.

Disposal Instructions

Unused or expired Romasulid must be disposed of according to local regulations for pharmaceutical waste handling. This often involves using a drug take-back program. Disposal by flushing the medicine down a toilet or pouring it into a drain is generally prohibited to protect the environment.